For the quarter ending 2016-12-31, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is set to announce its earnings on Feb 16/b. As per Zacks consensus estimate, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is set to report earnings per share (EPS) of $-1.55. The EPS is calculated as the arithmetic mean of all individual sell-side EPS estimates using the Zacks proprietary BNRI accounting methodology. As a reminder, the company’s EPS for the prior fiscal quarter was $-1.63.
Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) last traded at $49.37. (NASDAQ:AGIO) performance year to date is 10.52%. The 200 day simple moving average is 3.67%. The 200 simple moving average (SMA) is considered a key indicator by traders and market analysts for determining the overall long-term trend. The price level in a market that coincides with the 200 SMA is recognized as a major support when price is above the 200 SMA or resistance when price is below the 200 SMA level.
The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Weak. The market is in highly overbought territory. Beware of a trend reversal.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company’s products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Wall Street PR - Winning in 2017!http://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
2017 Most Disruptive Biotech IMLFFhttp://www.financialstrend.com
Disruptive biotech IMLFF decodes targeted drug delivery for stem cells
Enter The $100 Billion Gaming Markethttp://www.financialstrend.com
Gaming industry setup for explosive growth
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.financialstrend.com/disclaimer